ERI3

Across TCGA pan-cancer cohorts, ERI3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ERI3 data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ERI3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ERI3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, SCLC, and LIHC are the cancer types where ERI3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.118	0.844	<.001	24	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
LGG	OS	Median	All	0.214	0.889	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.637	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ERI3–OV (OS)

Open the OV breakdown →